Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

by Martin Tolar, Susan Abushakra, John A. Hey, Anton Porsteinsson, Marwan Sabbagh
Published 2020-08-01

Targeting autonomic flexibility to enhance cognitive training outcomes in older adults with mild cognitive impairment: study protocol for a randomized controlled trial

by Feng V. Lin, Kathi Heffner, Richard Gevirtz, Zhengwu Zhang, Duje Tadin, Anton Porsteinsson
Published 2021-08-01

Longitudinal Effects of Metabolic Syndrome on Alzheimer and Vascular Related Brain Pathology

by Feng Lin, Raymond Y. Lo, Daniel Cole, Simon Ducharme, Ding-Geng Chen, Mark Mapstone, Anton Porsteinsson
Published 2014-06-01

The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial

by Roberta W. Scherer, Lea Drye, Jacobo Mintzer, Krista Lanctôt, Paul Rosenberg, Nathan Herrmann, Prasad Padala, Olga Brawman-Mintzer, William Burke, Suzanne Craft, Alan J. Lerner, Allan Levey, Anton Porsteinsson, Christopher H. van Dyck, the ADMET 2 Research Group
Published 2018-01-01